Gastric Cancer
Conditions
Keywords
Gastric cancer, Neoadjuvant chemotherapy, Adjuvant chemotherapy, Time to chemotherapy, survival
Brief summary
he present study retrospectively analyzed the clinicopathological data of 524 patients diagnosed with LAGC who underwent D2 radical gastrectomy after NACT between January 2010 and December 2021 at 2 centers. This study was conducted in accordance with the ethical principles outlined in the World Medical Association's Declaration of Helsinki. Informed consent was obtained from all patients and their legal guardians. All procedures were approved by the institutional review board.
Detailed description
This is a retrospective, multicenter study.
Interventions
None listed
Sponsors
Fujian Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 84 Years
Healthy volunteers
No
Inclusion criteria
* (1) Locally advanced gastric cancer with preoperative clinical staging of cT2-4NxM0 before neoadjuvant chemotherapy. (2) No history of other malignant tumors. (3) No evidence of distant metastasis or invasion of adjacent organs. (4) Underwent gastrectomy after receiving neoadjuvant chemotherapy.
Exclusion criteria
* (1) History of prior gastrectomy. (2) History of acute cardiovascular diseases (such as cerebral or coronary artery injuries) within the past three months. (3) Emergency surgery. (4) Did not undergo postoperative adjuvant chemotherapy. (5) Lack of specific information regarding chemotherapy regimens. (6) Loss to follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year all-caused mortality, 3-year Gastric-Cancer Specific Motality | 3 years or 36 months. | Survival status at 3 years: survival, death, survival with tumor |
Countries
China
Outcome results
None listed